SIGLEC1 and breast neoplasm: To understand why CD169+ TAMs in primary human breast tumors were associated to these cell types and also to a worse prognosis (22), we set out to expand our analysis on the spatial associations between CD169+ TAMs and a broader panel of lymphocytes.